Consumers should stop use and report any adverse events.
New CGM eliminates fingersticks, introduces new data presentation.
Afamelanotide released through subcutaneous implant.
Also indciated to control bleeding and perioperative management.
Injection for leading cause of severe vision loss and legal blindness.
First new treatment of its kind in over 20 years.
Currently only approved for men and transgender women; future trials expected.
For granulomatosis with microscopic polyangiitis in children.
Now approved for risk reductions in patients with type 2 diabetes mellitus.
Monoclonal antibody for autoimmune and neurodegenerative disorders.